Helix BioPharma Corp. today announced that it has completed a private placement in Europe for gross proceeds of CAN $5,523,750. Helix issued 3,156,428 common shares and 3,156,428 common share purchase warrants in the European placement. Each common share purchase warrant entitles the holder to purchase one common share at a price of $2.45 until March 31st, 2008. Helix intends to use the net proceeds of the placement of $5.1 million (after finders' fees) to fund the pre-clinical and clinical development of products in its pipeline and for working capital and general corporate purposes.
Canada Newswire (http://www.newswire.ca/en/releases/archive/November2005/07/c1893.html)